Literature DB >> 17461452

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

Masahide Hamaguchi1, Takao Kojima, Noriyuki Takeda, Chisato Nagata, Jun Takeda, Hiroshi Sarui, Yutaka Kawahito, Naohisa Yoshida, Atsushi Suetsugu, Takahiro Kato, Junichi Okuda, Kazunori Ida, Toshikazu Yoshikawa.   

Abstract

AIM: To clarify whether nonalcoholic fatty liver disease (NAFLD) increases the risk of cardiovascular disease.
METHODS: We carried out a prospective observational study with a total of 1637 apparently healthy Japanese men and women who were recruited from a health check-up program. NAFLD was diagnosed by abdominal ultrasonography. The metabolic syndrome (MS) was defined according to the modified National Cholesterol Education Program (NCEP) ATP III criteria. Five years after the baseline evaluations, the incidence of cardiovascular disease was assessed by a self-administered questionnaire.
RESULTS: Among 1221 participants available for outcome analyses, the incidence of cardiovascular disease was higher in 231 subjects with NAFLD at baseline (5 coronary heart disease, 6 ischemic stroke, and 1 cerebral hemorrhage) than 990 subjects without NAFLD (3 coronary heart disease, 6 ischemic stroke, and 1 cerebral hemorrhage). Multivariate analyses indicated that NAFLD was a predictor of cardiovascular disease independent of conventional risk factors (odds ratio 4.12, 95% CI, 1.58 to 10.75, P = 0.004). MS was also independently associated with cardiovascular events. But simultaneous inclusion of NAFLD and MS in a multivariate model revealed that NAFLD but not MS retained a statistically significant correlation with cardiovascular disease.
CONCLUSION: Although both of them were predictors of cardiovascular disease, NAFLD but not MS retained a statistically significant correlation with cardiovascular disease in a multivariate model. NAFLD is a strong predictor of cardiovascular disease and may play a central role in the cardiovascular risk of MS.

Entities:  

Mesh:

Year:  2007        PMID: 17461452      PMCID: PMC4146902          DOI: 10.3748/wjg.v13.i10.1579

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.

Authors:  Hanna-Maaria Lakka; David E Laaksonen; Timo A Lakka; Leo K Niskanen; Esko Kumpusalo; Jaakko Tuomilehto; Jukka T Salonen
Journal:  JAMA       Date:  2002-12-04       Impact factor: 56.272

3.  Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics.

Authors:  Daad H Akbar; Abeer H Kawther
Journal:  Diabetes Care       Date:  2003-12       Impact factor: 19.112

Review 4.  Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?

Authors:  Shivakumar Chitturi; Geoffrey C Farrell; Jacob George
Journal:  J Gastroenterol Hepatol       Date:  2004-04       Impact factor: 4.029

5.  Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background.

Authors:  Sei-Ichiro Kojima; Norihito Watanabe; Makoto Numata; Tetsuhei Ogawa; Shohei Matsuzaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

6.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

7.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

8.  Fatty infiltration of liver in hyperlipidemic patients.

Authors:  N Assy; K Kaita; D Mymin; C Levy; B Rosser; G Minuk
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

Review 9.  Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.

Authors:  Brent A Neuschwander-Tetri; Stephen H Caldwell
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

10.  The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study.

Authors:  E Bonora; G Targher; G Formentini; F Calcaterra; S Lombardi; F Marini; L Zenari; F Saggiani; M Poli; S Perbellini; A Raffaelli; L Gemma; L Santi; R C Bonadonna; M Muggeo
Journal:  Diabet Med       Date:  2004-01       Impact factor: 4.359

View more
  189 in total

1.  The utility of Xenon-133 liver scan in the diagnosis and management of nonalcoholic fatty liver disease.

Authors:  Said A Al-Busafi; Peter Ghali; Philip Wong; Javier A Novales-Diaz; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

2.  Preclinical cardiac disease in nonalcoholic fatty liver disease with and without metabolic syndrome.

Authors:  Jasbir Makker; Hassan Tariq; Jonathan N Bella; Kishore Kumar; Chukwunonso Chime; Harish Patel; Muhammad Umar Kamal; Danial Shaikh; Vamshidhar Vootla; Bharat Bajantri; Umut Gomceli; Mohammad Alshelleh; Richard Peralta; Aiyi Zhang; Sridhar Chilimuri
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

Review 3.  Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.

Authors:  Enzo Bonora; Giovanni Targher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-08       Impact factor: 46.802

4.  Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference.

Authors:  Kunihiko Tominaga; Edward Fujimoto; Keiko Suzuki; Masayuki Hayashi; Masao Ichikawa; Yutaka Inaba
Journal:  Environ Health Prev Med       Date:  2009-01-31       Impact factor: 3.674

Review 5.  NAFLD/NASH in patients with type 2 diabetes and related treatment options.

Authors:  M G Radaelli; F Martucci; S Perra; S Accornero; G Castoldi; G Lattuada; G Manzoni; G Perseghin
Journal:  J Endocrinol Invest       Date:  2017-11-30       Impact factor: 4.256

6.  Correlation between nonalcoholic fatty liver and cardiovascular disease in elderly hemodialysis patients.

Authors:  Radojica V Stolic; Goran Z Trajkovic; Mirjana M Kostic; Sasa R Sovtic; Andrijana M Odalovic; Biljana D Krdzic; Maja V Sipic; Snezana Lazic; Zorica N Sojevic-Timotijevic
Journal:  Int Urol Nephrol       Date:  2016-02-23       Impact factor: 2.370

7.  Influence of Liver Disease on Perioperative Outcome After Bariatric Surgery in a Northern German Cohort.

Authors:  Stefan Wolter; Anna Duprée; Christina Coelius; Alexander El Gammal; Johannes Kluwe; Nina Sauer; Oliver Mann
Journal:  Obes Surg       Date:  2017-01       Impact factor: 4.129

8.  Additive effects of nicotine and high-fat diet on hepatic steatosis in male mice.

Authors:  Theodore C Friedman; Indrani Sinha-Hikim; Meher Parveen; Sonia M Najjar; Yanjun Liu; Michael Mangubat; Chang-Sung Shin; Alexei Lyzlov; Rasheed Ivey; Magda Shaheen; Samuel W French; Amiya P Sinha-Hikim
Journal:  Endocrinology       Date:  2012-10-23       Impact factor: 4.736

9.  Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol.

Authors:  Eline H van den Berg; Eke G Gruppen; Richard W James; Stephan J L Bakker; Robin P F Dullaart
Journal:  J Lipid Res       Date:  2018-11-19       Impact factor: 5.922

10.  Quantification of liver proton-density fat fraction in 7.1T preclinical MR systems: Impact of the fitting technique.

Authors:  Christoph Mahlke; Diego Hernando; Christina Jahn; Antonio Cigliano; Till Ittermann; Anne Mössler; Marie-Luise Kromrey; Grazyna Domaska; Scott B Reeder; Jens-Peter Kühn
Journal:  J Magn Reson Imaging       Date:  2016-05-19       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.